Revvity Q2 FY2026: $729.7 million revenue, guidance raised
Revvity's fiscal 2026 second quarter was a modest top line with a strong bottom line: revenue of $729.7 million grew 1.3% reported and 4.0% pro forma, and adjusted EPS of $1.41 beat the $1.2468 consensus by 13.1%, helped by $0.11 of tariff refunds. Read the Diagnostics-driven mix shift and the small guidance raise as the real story.
1 · Expected vs. Actual
Free preview belowGAAP EPS from continuing operations was $0.48, and adjusted EPS was $1.41 versus $1.18 a year ago, a 13.1% beat against the $1.2468 consensus. About $0.11 of that $1.41 came from tariff refunds, so the underlying beat is smaller but still real. Most of the GAAP-to-adjusted gap is $0.76 per share of intangible amortization.
Revenue of $729.7 million rose 1.3% from $720.3 million a year ago, but the pro forma view is better: $711.1 million versus $680.5 million, up 4.0%. Diagnostics did the work, with pro forma revenue up 12.0% and organic revenue up 11.0%, while Life Sciences fell 2.0% pro forma and 3.0% organic. Gross margin of 57.1% was up from 54.5% a year ago.
Log in to read 5 analyses a week for free
Create a free account to read 5 full earnings analyses each week — all five steps: expected vs. actual, guidance tracker, money flow, balance sheet and risks. Members get unlimited access.
Figures on this page come from the company's original SEC filings. The analysis is generated automatically and checked against validation rules, but may still contain errors or omissions. Not investment advice. · Generated 2026-09-17
Answers are based on the earnings release and the analysis above. Free accounts get 3 questions a week; members get 30 a day.